Abec-L Tablets

Introduction to Abec-L Tablets

Abec-L Tablets is a fixed-dose combination medication containing the active substances Abacavir (600mg) and Lamivudine (300mg). It belongs to the class of antiretroviral drugs known as Nucleoside Reverse Transcriptase Inhibitors (NRTIs). This medication is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection in adults, adolescents, and pediatric patients weighing at least 25 kg.

Both Abacavir and Lamivudine work by selectively inhibiting the HIV reverse transcriptase enzyme, an essential component the virus requires to replicate its genetic material. By blocking this enzyme, Abec-L Tablets stop the virus from multiplying, thereby reducing the viral load (amount of virus in the blood) and increasing the CD4+ cell count (immune cells). This action strengthens the immune system and significantly lowers the risk of developing HIV-associated secondary infections or complications.

Abec-L Tablets must be used under the strict supervision of an infectious disease specialist or HIV healthcare professional. It is vital to understand that while this medication effectively controls the replication of HIV, it is not a cure for HIV infection.

Critical Warning: A percentage of patients carrying a specific genetic marker known as the HLA-B*5701 allele can develop a severe, potentially life-threatening hypersensitivity (allergic) reaction to Abacavir. Patients must be screened for the HLA-B*5701 allele by a blood test before initiating treatment with Abec-L Tablets. Do not use this medication if you test positive for this genetic marker or if you have a known history of severe hypersensitivity to Abacavir or Lamivudine.

Before starting treatment, inform your doctor if you have a history of liver disease (such as Hepatitis B or C), kidney impairment, heart disease, high blood pressure, diabetes, or risk factors for metabolic conditions like lactic acidosis. Seek immediate emergency medical care if you develop symptoms of an allergic reaction (fever, rash, fatigue, nausea, vomiting, breathing difficulties) or signs of lactic acidosis (deep, rapid breathing, muscle weakness, severe stomach pain).

Uses of Abec-L Tablets

Uses of Abec-L Tablets:

• Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection in combination with other antiretroviral medications

• Reduction of viral load to maintain long-term viral suppression

• Preservation and improvement of immune system function (increasing CD4+ T-cell counts)

Therapeutic Effects of Abec-L Tablets

Abec-L Tablets work cooperatively to halt viral proliferation. Both components are intracellularly phosphorylated into active metabolites that directly compete with natural viral building blocks. This competitive inhibition terminates the synthesis of viral DNA chains during reverse transcription. Consequently, the medication effectively halts the expansion of HIV-1 within the host immune system, minimizing structural immune degradation and allowing the body's natural defense mechanisms to rebuild.

Interaction of Abec-L Tablets with other drugs

It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Abec-L Tablets, potentially affecting their effectiveness or causing serious side effects. Notable interactions include:

• Emtricitabine: Should not be co-administered with Lamivudine as they are highly similar and compete with each other, rendering the combination ineffective.

• Methadone: Abacavir may increase the clearance of methadone, occasionally requiring a re-evaluation of methadone dosages.

• Ribavirin / Interferon alpha: Used for treating Hepatitis C; combined use with Lamivudine may increase the risk of severe liver toxicity or lactic acidosis.

• Trimethoprim/Sulfamethoxazole (Co-trimoxazole): Can increase the concentration of Lamivudine in the blood; monitoring is advised if high doses are used.

More Information about Abec-L Tablets

• Keep out of reach of children and pets.

• Store in a dry place at a temperature not exceeding 30°C.

• Keep the tablets stored inside their original moisture-resistant container or bottle, tightly capped.

How to consume Abec-L Tablets

Abec-L Tablets are oral medications intended to be swallowed whole with a glass of water. They should not be crushed or split if used at full dosage. They can be taken with or without food. To achieve optimal viral suppression, it is absolutely essential to take this medication exactly as prescribed, at the same time every single day. Adherence is critical; skipping doses can cause the virus to develop genetic resistance to the medication.

Safety Advice for Abec-L Tablets

Breast Feeding

Unsafe HIV-infected mothers should not breastfeed to avoid transmitting the virus to the infant. Additionally, Abacavir and Lamivudine pass into breast milk and can cause adverse side effects in a nursing child.

Alcohol

Caution Avoid or strictly limit alcohol consumption while taking Abec-L Tablets. Alcohol increases the workload on the liver and elevates the risk of developing liver toxicity, pancreatitis, or metabolic imbalances.

Liver

Caution Abec-L Tablets are processed by the liver. Patients with pre-existing mild liver impairment require close monitoring, while the drug is typically not recommended for moderate-to-severe hepatic impairment. Regular liver function tests (LFTs) are mandatory.

Lungs

Consult Your Doctor Respiratory symptoms like shortness of breath or a cough can sometimes be a sign of a severe Abacavir hypersensitivity reaction rather than a chest infection. Consult your doctor immediately if any respiratory discomfort develops.

Driving

Consult Your Doctor Abec-L Tablets generally do not cheat your ability to drive or operate machinery. However, if you experience dizziness, headache, or profound fatigue, avoid driving until you feel fully alert.

Pregnancy

Consult Your Doctor Abec-L Tablets should be used during pregnancy only if the potential therapeutic benefits heavily outweigh the potential risks to the fetus. Discuss your options thoroughly with your specialist.

Side Effects of Abec-L Tablets

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.

Common side effects of Abec-L Tablets are:

• Nausea, vomiting, or diarrhea

• Headaches or dizziness

• Fatigue, lethargy, or generalized weakness

• Trouble sleeping (insomnia) or unusual dreams

• Mild skin rashes

Serious side effects of Abec-L Tablets are:

• Abacavir Hypersensitivity Reaction: (Fever, severe rash, extreme fatigue, body aches, sore throat, cough, abdominal pain).

• Lactic Acidosis: (Deep, rapid breathing, unexpected muscle pain, cold extremities, severe nausea, fast heart rate).

• Hepatomegaly with Steatosis (Severe Liver Issues): (Yellowing eyes/skin, dark urine, severe pain in the upper right side of the abdomen).

• Immune Reconstitution Syndrome: (An overactive inflammatory response against old or hidden infections as the immune system recovers).

Word of Advice

Always carry your Abacavir Warning Card (usually provided with the packaging) with you at all times. It lists the crucial symptoms of an allergic reaction. If you stop taking Abec-L Tablets due to a suspected allergic reaction, never restart taking it, as doing so can trigger an immediate, fatal drop in blood pressure. Ensure you keep all appointments for laboratory tests, including liver function, kidney function, and viral load measurements. Do not stop taking this medication unless explicitly instructed by your HIV care specialist.

FAQs about Abec-L Tablets

Q1. What is the HLA-B*5701 genetic test and why is it mandatory before taking Abec-L? The HLA-B*5701 test is a genetic screening blood test. It determines if you are at a high risk of developing a severe, life-threatening allergic reaction to Abacavir. If the test is positive, your doctor will select an alternative medication instead of Abec-L.

Q2. What should I do if I suspect I am having an allergic reaction to Abec-L Tablets? If you develop a fever, rash, or respiratory issues (like a cough or shortness of breath) along with nausea or fatigue, stop taking the medication and contact your doctor or go to the nearest emergency room immediately.

Q3. Can Abec-L Tablets prevent me from passing HIV to others? Taking Abec-L Tablets and achieving an "undetectable" viral load effectively reduces the risk of transmitting HIV through sexual contact to zero. However, it is still recommended to practice safe sex and use condoms to prevent other sexually transmitted infections (STIs).

Q4. What happens if I have chronic Hepatitis B and stop taking Abec-L Tablets? Lamivudine (one of the components in Abec-L) is also active against the Hepatitis B virus (HBV). If you have both HIV and HBV and suddenly stop taking this medicine, your Hepatitis B infection can suddenly flare up and cause severe liver damage. Never stop treatment without your doctor's explicit guidance.

Q5. Can I take standard antacids or vitamin supplements along with Abec-L Tablets? Most standard antacids do not significantly interfere with Abec-L. However, you should always provide a comprehensive list of all supplements and over-the-counter drugs to your doctor to ensure no specific interactions occur.

Fact Box of Abec-L Tablets

• Molecule name: Abacavir (600mg) + Lamivudine (300mg)

• Therapeutic class: Antiretrovirals

• Pharmacological class: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

• Indications: 1. Management and treatment of HIV-1 infection in adults and children weighing 25 kg or more.

References

1. Shuter J, et al. Fixed-dose combination of abacavir and lamivudine for the treatment of HIV-1 infection. https://pubmed.ncbi.nlm.nih.gov/16542121/

2. National Institutes of Health. Clinical Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. [Updated 2026]. Available from: https://clinicalinfo.hiv.gov/

3. World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. https://www.who.int/publications/i/item/9789240031593

4. Food and Drug Administration (FDA). Epzicom (Abacavir and Lamivudine) Prescribing Information and Boxed Warning Data. https://www.accessdata.fda.gov/

Disclaimer

Medipoint India’s primary intention is to ensure that its consumers get accurate, trustworthy, and expert-reviewed information. The contents of this website are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Medipoint India. Our mission is to support, not replace, the doctor-patient relationship.

- No EU import duties.
- Ships within 1-2 business days.
- Ships in our fully recyclable and biodegradable signature boxes.